OPTIVAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Optivar, and when can generic versions of Optivar launch?
Optivar is a drug marketed by Mylan Speciality Lp and is included in one NDA.
The generic ingredient in OPTIVAR is azelastine hydrochloride. There are twelve drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Optivar
A generic version of OPTIVAR was approved as azelastine hydrochloride by APOTEX INC on April 30th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OPTIVAR?
- What are the global sales for OPTIVAR?
- What is Average Wholesale Price for OPTIVAR?
Summary for OPTIVAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 114 |
Patent Applications: | 1,692 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OPTIVAR at DailyMed |
![OPTIVAR drug patent expirations Drug patent expirations by year for OPTIVAR](/p/graph/s/t/OPTIVAR-patent-expirations.png)
Paragraph IV (Patent) Challenges for OPTIVAR
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
OPTIVAR | Ophthalmic Solution | azelastine hydrochloride | 0.05% | 021127 | 1 | 2006-12-13 |
US Patents and Regulatory Information for OPTIVAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mylan Speciality Lp | OPTIVAR | azelastine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021127-001 | May 22, 2000 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPTIVAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Mylan Speciality Lp | OPTIVAR | azelastine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021127-001 | May 22, 2000 | ⤷ Sign Up | ⤷ Sign Up |
Mylan Speciality Lp | OPTIVAR | azelastine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021127-001 | May 22, 2000 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OPTIVAR
See the table below for patents covering OPTIVAR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2506388 | ⤷ Sign Up | |
Japan | 2911460 | ⤷ Sign Up | |
Denmark | 174928 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPTIVAR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1519731 | 92269 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE |
0316633 | 99C0012 | Belgium | ⤷ Sign Up | PRODUCT NAME: AZELASTINE HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: 31 IS 113 F 13 19981021; FIRST REGISTRATION: GB PL 08336/0083 19980218 |
1519731 | 13C0067 | France | ⤷ Sign Up | PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |